retatrutide phase 2 trial results weight loss Results:Trial Data and FDA Status 🚨 BREAKING: Retatrutide Shows “Bariatric-Level”

check your specific plan rules.

Data from the European LEOSS registry as well as other data show an additive effect of obesity, diabetes, and hypertension on the risk of mortality, which is higher in young and middle-aged patients (1855 years)

[11] [12] This delayed gastric emptying is largely responsible for the prolonged sense of satiety many people experience, but it also underlies some of the gastrointestinal side effects associated with the drug class, including nausea, bloating, and early fullness

Serious but Less Common Side Effects: Pancreatitis: Although rare, there is a risk of acute pancreatitis in some individuals

Less common but serious risks noted in prescribing information for GLP-1 medications include pancreatitis, gallbladder disease, and kidney injury in the setting of dehydration from gastrointestinal side effects